BRCA1 and malignant colon neoplasm: We then evaluated whether the reduction of BRCA-1 by DPE/ceapinA7- or Thapsigargin/ceapinA7 could potentiate the cytotoxic effect of a DNA damaging agent such as Adriamycin, widely used to treat colon cancer [21].